Single fraction SABR

RADIATION2 trials

Sponsors

Trans Tasman Radiation Oncology Group, Robert Olson

Conditions

CancerMetastases to the LungOligometastatic DiseaseOligoprogressionQuality of LifeToxicity Due to Radiotherapy

Unknown Phase

A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

CompletedNCT01965223

Trans Tasman Radiation Oncology GroupCancer, Metastases to the Lung

Start: 2015-02-04End: 2020-07-27Updated: 2020-11-04

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

RecruitingNCT05784428

Robert OlsonOligometastatic Disease, Oligoprogression, Quality of Life +1

Start: 2025-04-16End: 2035-05-30Target: 598Updated: 2026-06-25

Related Papers

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

BMC Cancer2024-02-031 citations

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)

JAMA Oncology2021-08-2984 citations

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)

BMC Cancer2016-03-0443 citations